Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAn updated page revision tag v3.5.4 is displayed, replacing the previous v3.5.3. This reflects a maintenance or update to the page's versioning rather than changes to trial data or content.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check38 days agoChange DetectedThe page’s footer software/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check74 days agoChange DetectedSite revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check81 days agoChange DetectedFooter revision updated from Revision: v3.4.2 to Revision: v3.4.3.SummaryDifference0.1%

- Check110 days agoChange DetectedRevision updated to v3.4.2 and the prior funding/operating-status notice was removed; these are site-wide housekeeping changes rather than updates to study details.SummaryDifference0.4%

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.